The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date.
The 2020/21 programme builds on the successes of the 2019/20 RUPs programme, with themes selected via an open, staged, selection process.
The following innovations will be supported through the Rapid Uptake Products (RUP) Programme for 2020/21:
Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors
The Rapid Uptake Product (RUP) for lipid management is a novel, NICE-endorsed clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine along the evidence-based pathway. The pathway includes three medicines: high intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20).
Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
FeNO (fractional exhaled nitric oxide) is a point of care test to measure type two inflammation in airways, which augments and supports the accuracy of asthma diagnosis. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma.
Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab
Biological therapies can transform patient lives by reducing long-term side effects of other treatments (e.g. oral corticosteroids (OCS)) and can also reduce the number of exacerbations and life-threatening asthma attacks. The aim of this innovation will be to improve patient care and outcomes by providing a better treatment option for patients with severe asthma.
Tamoxifen for prevention of breast cancer for women at known risk
For women at known risk, Tamoxifen can halve the risk of breast cancer when taken over five years. However, uptake of Tamoxifen is low in clinical practice (roughly 10% in England) due to factors such as access to specialist risk assessment whereby considerations such as family history of reproductive cancers and breast density are reviewed. The aim of this innovation is to improve patient care and outcomes, and ultimately prevent avoidable breast cancer.
Three Rapid Uptake Products from the 2019/20 programme will continue through 2020/21:
- Placental growth factor (PIGF) based tests to help rule out pre-eclampsia quickly so that pregnant women receive the most appropriate care
- HeartFlow FFRCT – analysis which creates a 3D model of the coronary arteries to help clinicians to rapidly diagnose patients with suspected coronary artery disease from coronary CT angiography
- PCSK9 inhibitors – will continue as part of a wider Lipid Management workstream. PCSK9 inhibitors are for the treatment of very high cholesterol, and are used together with a statin-type cholesterol-lowering medicine, or for patients who are unable to take or tolerate a statin.